Comparison in Efficacy and Safety of Three Adjuvant Chemotherapy of Stage Ⅲ Colorectal Cancer
- VernacularTitle:Ⅲ期结直肠癌术后三种辅助化疗方案的疗效及安全性比较
- Author:
Peixin YANG
;
Ruochuan CHENG
;
Chang DIAO
;
Jianming ZHANG
;
Xiaoping WEI
;
Yanjun SU
- Publication Type:Journal Article
- Keywords:
Advanced colorectal cancer;
Oxaliplatin;
Capecitabine;
Disease-free survival;
Adverse effect
- From:
Journal of Kunming Medical University
2007;0(S1):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective TO evaluate the efficacy and safety of three adjuvant chemotherapy regimens after curative resection for stage III colorectal cancer,and present clinical evidence for proper choice.Methods 256 cases with stage Ⅲ colorectal cancer randomized to receive de Gramont,modified FOLFOX4(mFOLFOX4) and XELOX regimens.3-year disease-free survival(DFS) and overall survival(OS) were compared within the three groups and subgroups.Therapeutic adverse events were recorded and analyzed with Kaplan-Meier.Results Compared with de Gramont regimen,mFOLFOX4 and XELOX had superior efficacy.The two former could significantly improve 3-year DFS(79.7% vs.66.2%,P=0.015;81.5% vs.66.2%,P=0.004) and medium survival time(40.2 mon vs.37.8 mon,P=0.024;41.4 mon vs.37.8 mon,P=0.014).Meanwhile they could respectively decrease the ratio of recurrence risk 18%(P=0.024) and 21%(P=0.003).The relative benefit of mFOLFOX4 versus XELOX didn't differ for 3-year DFS [hazard ratio(HR): 0.84,95% confidence interval(CI): 0.79～1.12,P=0.13] and OS(HR: 0.87,95%CI: 0.84~1.06,P=0.54).In advanced analysis of DFS in subgroup,XELOX had better trend of survival advantage.mFOLFOX4 had higher adverse events within these regimens,especially in grade 3 or 4 neutropenia and peripheral neurologic adverse events.Conclusion XELOX maintains its efficacy and safety ratio in advanced colorectal cancer.Patients have good tolerance and compliance.The regiment is deserved to be applied in clinic.
